GlassScriptPhysician profile
Nicholas G Hanson
NPI 1710149794
$6,343.98
in general payments reported to CMS, 2019-2025
48 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $515 · 2021: $1,978 · 2022: $864 · 2023: $812 · 2024: $786 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,214.06 | 2021 | |
| Abbvie INC. | $559.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $454.54 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Viiv Healthcare Company | $376.55 | 2023-2025 | Apretude |
| Novo Nordisk INC | $277.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $259.36 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.83 | 2019-2024 | Jardiance, Synjardy |
| Amgen INC. | $251.04 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $247.30 | 2019-2024 | Veozah |
| Lilly USA, LLC | $236.56 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $217.54 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $213.16 | 2019-2024 | |
| Amarin Pharma, INC. | $163.31 | 2019-2022 | |
| Exact Sciences Corporation | $148.09 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $126.30 | 2022-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.